Results 11 to 20 of about 6,976 (207)
Molnupiravir: First Approval [PDF]
Drugs, 2022 Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback Biotherapeutics for the prevention and treatment of Coronavirus disease 2019 (COVID-19).
Yahiya Y. Syed (6594444)
openaire +3 more sources
Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
Viruses, 2023 Porcine epidemic diarrhea virus (PEDV) is a swine coronavirus that is highly infectious and prone to variation. Vaccines derived from traditional PEDV strains provide less protection against PEDV-variant strains. Furthermore; there is a complex diversity
Zi-Xin Huang +3 more
doaj +2 more sources
A Nanopore Based Molnupiravir Sensor
ACS Sensors, 2022 Nucleoside analogues are reagents that resemble the structure of natural nucleosides and are widely applied in antiviral and anticancer therapy. Molnupiravir, a recently reported nucleoside analogue drug, has shown its inhibitory effect against SARS-CoV-2.
Wendong Jia +5 more
openaire +3 more sources
Molnupiravir for treating COVID-19
Cochrane Database of Systematic ReviewsFive years from the start of the COVID-19 pandemic, morbidity and mortality have subsided. Vaccines have contributed to reducing the risk of infection and severe disease. However, new COVID-19 variants continue to emerge, and the role of oral antivirals such as molnupiravir in preventing progression of disease or hospitalisation must be assessed.To ...
Gayle S Tatz +8 more
openaire +3 more sources
Why Molnupiravir Fails in Hospitalized Patients
mBio, 2022 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has radically altered daily life.
Ashley N. Brown +6 more
doaj +3 more sources
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Antibiotics, 2021 Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths.
Ching-Chi Lee +2 more
doaj +2 more sources
A Bayesian Analysis of the Molnupiravir Trial Data
, 2021 On October 1st 2021, Merck issued a press release claiming that "molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19." Specifically ...
Eric-Jan Wagenmakers +1 more
openaire +3 more sources
Computational Analysis of Molnupiravir [PDF]
International Journal of Molecular Sciences, 2022 In this work, we report in-depth computational studies of three plausible tautomeric forms, generated through the migration of two acidic protons of the N4-hydroxylcytosine fragment, of molnupiravir, which is emerging as an efficient drug to treat COVID-19. The DFT calculations were performed to verify the structure of these tautomers, as well as their
Artem Sharov +4 more
openaire +3 more sources
Molnupiravir: coding for catastrophe [PDF]
Nature Structural & Molecular Biology, 2021 Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication
Brandon, Malone, Elizabeth A, Campbell
openaire +2 more sources
Molnupiravir: Mechanism of action, clinical, and translational science
Clinical and Translational ScienceMolnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP).
Brian M. Maas +9 more
doaj +2 more sources